Geron (GERN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
7 Apr, 2026Executive summary
The annual meeting will be held virtually on May 20, 2026, with shareholders able to vote and submit questions online.
Four main proposals are up for vote: election of three directors, amendment of the 2018 Equity Incentive Plan, advisory approval of executive compensation, and ratification of Ernst & Young LLP as auditor.
The board recommends voting in favor of all proposals.
Proxy materials are primarily distributed electronically to reduce costs and environmental impact.
Voting matters and shareholder proposals
Proposal 1: Elect three Class III directors for terms expiring in 2029.
Proposal 2: Approve amendment to the 2018 Equity Incentive Plan, increasing shares available by 4,500,000 and incentive stock option limit by 9,000,000.
Proposal 3: Advisory vote on executive compensation (say-on-pay).
Proposal 4: Ratify Ernst & Young LLP as independent auditor for 2026.
No other shareholder proposals were received for this meeting.
Board of directors and corporate governance
Board consists of eight members, seven of whom are independent; CEO is the only non-independent director.
Board is classified into three staggered classes; directors serve three-year terms.
Board committees include Audit, Compensation, and Nominating and Corporate Governance, all composed of independent directors.
Board leadership is separated between Chair and CEO roles.
Board diversity includes four women and five men as of March 2026.
Latest events from Geron
- RYTELO’s expanding use and strong clinical data drive steady growth and future pipeline potential.GERN
Goldman Sachs 47th Annual Global Healthcare Conference 20268 Jun 2026 - All proposals passed; clinical and commercial strategies advancing, with key trial data ahead.GERN
AGM 202620 May 2026 - Commercial momentum, clinical validation, and updated guidelines drive growth and profitability.GERN
Stifel 2026 Targeted Oncology Virtual Forum20 May 2026 - RYTELO posts record Q1 revenue, expands in second-line MDS, and prepares for key myelofibrosis readout.GERN
Bank of America Global Healthcare Conference 202613 May 2026 - Q1 2026 revenue rose 31% to $51.8M, with net loss narrowing and strong RYTELO demand.GERN
Q1 20266 May 2026 - RYTELO delivers durable transfusion independence in LR-MDS and targets expansion into myelofibrosis.GERN
Corporate presentation6 May 2026 - RYTELO targets disease biology in MDS and MF, driving robust growth and future expansion.GERN
Barclays 28th Annual Global Healthcare Conference25 Apr 2026 - Imetelstat anchors second-line MDS therapy, with strong growth and pivotal myelofibrosis data ahead.GERN
25th Annual Needham Virtual Healthcare Conference13 Apr 2026 - Votes include director elections, equity plan changes, executive pay, and auditor ratification.GERN
Proxy filing7 Apr 2026